# A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

> **NCT04247984** · PHASE2 · COMPLETED · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 264 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Irinotecan
- **DRUG:** 5-FU
- **DRUG:** CF
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT04247984
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2021-04-01
- **Final completion:** 2022-01-31
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2022-03-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04247984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04247984, "A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04247984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*